We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories’ (ABT - Free Report) growth in the third quarter of 2024 can be attributed to strong sales recovery within the Nutrition business, driven by the robust sales performance of Ensure, the company’s market-leading complete and balanced nutrition brand. The company is driving solid growth in emerging markets within the EPD business. However, the runoff of COVID testing revenues and currency fluctuations may restrict Abbott’s growth potential.
In the past year, this Zacks Rank #3 (Hold) company’s shares have risen 1.6% compared with the industry’s 11% growth and the S&P 500 composite’s 27.8% increase.
The leading at-home healthcare company has a market capitalization of $196.50 billion. Abbott beat on earnings in each of the trailing four quarters, delivering an average surprise of 1.64%.
ABT’s Tailwinds
Sales Recovery Within Nutrition: Abbott’s Nutrition business has strongly gained its market share since the beginning of 2023. The overall business is particularly expanding on strong global demand for the company’s adult nutrition products.
In the third quarter of 2024, the company reported 3.4% organic growth within this business, backed by a strong 9.1% improvement in Adult Nutrition. This was led by strong sales of Ensure.
International adult nutrition registered high single-digit growth on the back of strong market adoption of the company’s Ensure and Glucerna brands. Within Pediatric Nutrition, ABT reported 12% organic growth in the United States on a year-over-year basis, favored by continued market share gains in the infant formula business in this region.
EPD Business Set for Sustainable Growth: Abbott’s EPD business operates solely in emerging geographies, with leading positions in many of the world's largest and fastest-growing pharmaceutical markets for branded generics. Banking on the successful execution of its Branded Generic operating model, EPD is well-positioned for sustained growth in many of these growing pharmaceutical markets.
The company is also strategically progressing with its advancement in biosimilars. Recently, it completed additional agreements to obtain access to biosimilar versions of market-leading autoimmune disease and GLP1 medications.
Abbott’s EPD sales in the third quarter of 2024 increased 7% organically. In key emerging markets, organic sales improved 5.4% year over year, led by growth in several geographies and therapeutic areas, including gastroenterology, cardiometabolic and central nervous system/pain management.
ABT’s Headwinds
Runoff Of COVID Testing Revenues: During the COVID-19 public health emergency, Abbott’s diagnostic tests witnessed stupendous revenue growth. This was due to the increasing demand for testing.
Image Source: Zacks Investment Research
However, following the official ending of the public health emergency in May 2023, Abbott is experiencing a continuous decline in COVID-19 testing-related demand. In Rapid Diagnostics, sales decreased 3% organically in the third quarter of 2024. Within Molecular Diagnostics, too, organic sales plunged 2.1% year over year.
Foreign Exchange Translation Impacts Sales: Foreign exchange is a major headwind for Abbott because a considerable percentage of its revenues come from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets. In the third quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 2.5% on sales.
Abbott’s Estimates Trend
The Zacks Consensus Estimate for 2024 earnings per share has remained unchanged at $4.67 in the past 30 days.
The Zacks Consensus Estimate for 2024 revenues is pegged at $42.00 billion, indicating a 4.7% rise from the year-ago reported number.
Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. HAE’s shares have risen 3.6% compared with the industry’s 19.9% growth in the past year.
Penumbra, carrying a Zacks Rank #2 at present, has an estimated 2024 earnings growth rate of 33.5% compared with the industry’s 15.9%. Shares of Penumbra have risen 3.2% compared with the industry’s 14.5% growth in the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.
Globus Medical, carrying a Zacks Rank #3 at present, has a long-term estimated growth rate of 14.1%. Shares of the company have rallied 81.8% compared with the industry’s 14.5% growth. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Reasons to Retain ABT Stock in Your Portfolio Now
Abbott Laboratories’ (ABT - Free Report) growth in the third quarter of 2024 can be attributed to strong sales recovery within the Nutrition business, driven by the robust sales performance of Ensure, the company’s market-leading complete and balanced nutrition brand. The company is driving solid growth in emerging markets within the EPD business. However, the runoff of COVID testing revenues and currency fluctuations may restrict Abbott’s growth potential.
In the past year, this Zacks Rank #3 (Hold) company’s shares have risen 1.6% compared with the industry’s 11% growth and the S&P 500 composite’s 27.8% increase.
The leading at-home healthcare company has a market capitalization of $196.50 billion. Abbott beat on earnings in each of the trailing four quarters, delivering an average surprise of 1.64%.
ABT’s Tailwinds
Sales Recovery Within Nutrition: Abbott’s Nutrition business has strongly gained its market share since the beginning of 2023. The overall business is particularly expanding on strong global demand for the company’s adult nutrition products.
In the third quarter of 2024, the company reported 3.4% organic growth within this business, backed by a strong 9.1% improvement in Adult Nutrition. This was led by strong sales of Ensure.
International adult nutrition registered high single-digit growth on the back of strong market adoption of the company’s Ensure and Glucerna brands. Within Pediatric Nutrition, ABT reported 12% organic growth in the United States on a year-over-year basis, favored by continued market share gains in the infant formula business in this region.
EPD Business Set for Sustainable Growth: Abbott’s EPD business operates solely in emerging geographies, with leading positions in many of the world's largest and fastest-growing pharmaceutical markets for branded generics. Banking on the successful execution of its Branded Generic operating model, EPD is well-positioned for sustained growth in many of these growing pharmaceutical markets.
The company is also strategically progressing with its advancement in biosimilars. Recently, it completed additional agreements to obtain access to biosimilar versions of market-leading autoimmune disease and GLP1 medications.
Abbott’s EPD sales in the third quarter of 2024 increased 7% organically. In key emerging markets, organic sales improved 5.4% year over year, led by growth in several geographies and therapeutic areas, including gastroenterology, cardiometabolic and central nervous system/pain management.
ABT’s Headwinds
Runoff Of COVID Testing Revenues: During the COVID-19 public health emergency, Abbott’s diagnostic tests witnessed stupendous revenue growth. This was due to the increasing demand for testing.
Image Source: Zacks Investment Research
However, following the official ending of the public health emergency in May 2023, Abbott is experiencing a continuous decline in COVID-19 testing-related demand. In Rapid Diagnostics, sales decreased 3% organically in the third quarter of 2024. Within Molecular Diagnostics, too, organic sales plunged 2.1% year over year.
Foreign Exchange Translation Impacts Sales: Foreign exchange is a major headwind for Abbott because a considerable percentage of its revenues come from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets. In the third quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 2.5% on sales.
Abbott’s Estimates Trend
The Zacks Consensus Estimate for 2024 earnings per share has remained unchanged at $4.67 in the past 30 days.
The Zacks Consensus Estimate for 2024 revenues is pegged at $42.00 billion, indicating a 4.7% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Penumbra (PEN - Free Report) and Globus Medical (GMED - Free Report) .
Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. HAE’s shares have risen 3.6% compared with the industry’s 19.9% growth in the past year.
HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra, carrying a Zacks Rank #2 at present, has an estimated 2024 earnings growth rate of 33.5% compared with the industry’s 15.9%. Shares of Penumbra have risen 3.2% compared with the industry’s 14.5% growth in the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.
Globus Medical, carrying a Zacks Rank #3 at present, has a long-term estimated growth rate of 14.1%. Shares of the company have rallied 81.8% compared with the industry’s 14.5% growth. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%.